Skip to main content

Peer Review reports

From: Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study

Original Submission
28 Mar 2022 Submitted Original manuscript
3 Apr 2022 Reviewed Reviewer Report
14 Apr 2022 Reviewed Reviewer Report - Eleonora De Matteis
28 Apr 2022 Author responded Author comments - Armin Scheffler
Resubmission - Version 2
28 Apr 2022 Submitted Manuscript version 2
30 Apr 2022 Editorially accepted
11 May 2022 Article published 10.1186/s10194-022-01426-8

You can find further information about peer review here.

Back to article page